ACM
IRD

ADAR1 Capital Management’s Opus Genetics IRD Stock Holding History

ADAR1 Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.41M Buy
1,849,004
+1,809,004
+4,523% +$6.26M 0.5% 50
2025
Q4 		$80.4K Buy
+40,000
New +$81.2K 0.01% 258

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ADAR1 Capital Management's IRD Position: Q1 2026 in Review

ADAR1 Capital Management increased its Opus Genetics (IRD) stake by 4,523% in Q1 2026, buying an estimated $6.26M and bringing the position to 1,849,004 shares worth $8.41M. The position accounts for 0.5% of the portfolio, ranked #50.

ADAR1 Capital Management first reported a position in IRD in Q4 2025 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • ADAR1 Capital Management held 1,849,004 shares of Opus Genetics worth $8.41M as of Q1 2026.
  • ADAR1 Capital Management bought 1,809,004 Opus Genetics shares in Q1 2026, an estimated $6.26M.
  • Opus Genetics made up 0.5% of ADAR1 Capital Management's portfolio in Q1 2026, its #50 holding.
  • ADAR1 Capital Management first reported a position in Opus Genetics in Q4 2025 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.